Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Perleth, M.
and
Lühmann, D.
2010.
Nutzen- und Wirtschaftlichkeitsbewertung der biomedizinischen Technik.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz,
Vol. 53,
Issue. 8,
p.
825.
Wlodarczyk, John
Reid, Christopher M.
and
Pater, Glen
2011.
Funding Linked to Ongoing Research: Impact of the Bosentan Patient Registry on Pricing in Australia.
Value in Health,
Vol. 14,
Issue. 6,
p.
961.
Lange, Stefan
2011.
Schließen von „Evidenzlücken“.
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen,
Vol. 105,
Issue. 9,
p.
652.
Mendelssohn, David C.
and
McFarlane, Phil
2011.
Conditionally Funded Field Evaluations—A Solution to the Economic Barriers Limiting Evidence Generation in Dialysis?.
Seminars in Dialysis,
Vol. 24,
Issue. 5,
p.
556.
Park, Silvia
and
Lee, Sang Moo
2011.
Evidence-based healthcare and the need of conditional decision.
Journal of the Korean Medical Association,
Vol. 54,
Issue. 12,
p.
1319.
Varela-Lema, Leonor
Merino, Gerardo Atienza
García, Marisa López
Martínez, María Vidal
Triana, Elena Gervas
and
Mota, Teresa Cerdá
2011.
Demandas y expectativas de la evaluación de tecnologías sanitarias en Galicia. Análisis cualitativo desde la perspectiva de decisores y clínicos.
Gaceta Sanitaria,
Vol. 25,
Issue. 6,
p.
454.
Perleth, M.
and
Lühmann, D.
2011.
Nutzen- und Wirtschaftlichkeitsbewertung der biomedizinischen Technik.
Der Onkologe,
Vol. 17,
Issue. 5,
p.
420.
Varela-Lema, Leonor
Ruano-Ravina, Alberto
Mota, Teresa Cerdá
Ibargoyen-Roteta, Nora
Imaz, Inaki
Gutiérrez-Ibarluzea, Inaki
Blasco-Amaro, Juan Antonio
Soto-Pedre, Enrique
and
Sampietro-Colom, Laura
2012.
POST-INTRODUCTION OBSERVATION OF HEALTHCARE TECHNOLOGIES AFTER COVERAGE: THE SPANISH PROPOSAL.
International Journal of Technology Assessment in Health Care,
Vol. 28,
Issue. 3,
p.
285.
Poulin, Paule
Austen, Lea
Kortbeek, John B.
and
Lafrenière, René
2012.
New Technologies and Surgical Innovation.
Surgical Innovation,
Vol. 19,
Issue. 2,
p.
187.
Dubner, Sergio
Auricchio, Angelo
Steinberg, Jonathan S.
Vardas, Panos
Stone, Peter
Brugada, Josep
Piotrowicz, Ryszard
Hayes, David L.
Kirchhof, Paulus
Breithardt, Günter
Zareba, Wojciech
Schuger, Claudio
Aktas, Mehmet K.
Chudzik, Michal
Mittal, Suneet
and
Varma, Niraj
2012.
ISHNE/EHRA Expert Consensus on Remote Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs).
Annals of Noninvasive Electrocardiology,
Vol. 17,
Issue. 1,
p.
36.
Nachtnebel, Anna
Geiger-Gritsch, Sabine
Hintringer, Katharina
and
Wild, Claudia
2012.
Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria.
Health Policy,
Vol. 104,
Issue. 1,
p.
1.
Persson, Ulf
Svensson, Johanna
and
Pettersson, Billie
2012.
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing.
Applied Health Economics and Health Policy,
Vol. 10,
Issue. 4,
p.
217.
Koerber, Florian
Rolauffs, Bernd
and
Rogowski, Wolf
2013.
Early Evaluation and Value-Based Pricing of Regenerative Medicine Technologies.
Regenerative Medicine,
Vol. 8,
Issue. 6,
p.
747.
Morgan, Steven G.
Thomson, Paige A.
Daw, Jamie R.
and
Friesen, Melissa K.
2013.
Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
Health Policy,
Vol. 112,
Issue. 3,
p.
248.
Kirisits, Andreas
and
Redekop, W. Ken
2013.
The Economic Evaluation of Medical Devices.
Applied Health Economics and Health Policy,
Vol. 11,
Issue. 1,
p.
15.
Garrison, Louis P.
Towse, Adrian
Briggs, Andrew
de Pouvourville, Gerard
Grueger, Jens
Mohr, Penny E.
Severens, J.L. (Hans)
Siviero, Paolo
and
Sleeper, Miguel
2013.
Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force.
Value in Health,
Vol. 16,
Issue. 5,
p.
703.
Lee, Min
and
Ahn, Jeonghoon
2014.
The current status and future direction of Korean health technology assessment system.
Journal of the Korean Medical Association,
Vol. 57,
Issue. 11,
p.
906.
Olberg, Britta
Perleth, Matthias
and
Busse, Reinhard
2014.
The new regulation to investigate potentially beneficial diagnostic and therapeutic methods in Germany: Up to international standard?.
Health Policy,
Vol. 117,
Issue. 2,
p.
135.
Chapman, A. M.
Taylor, C. A.
and
Girling, A. J.
2014.
Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP).
Applied Health Economics and Health Policy,
Vol. 12,
Issue. 4,
p.
347.
Franken, Margreet G.
Gaultney, Jennifer G.
Blommestein, Hedwig M.
Huijgens, Peter C.
Sonneveld, Pieter
Redekop, William K.
and
Uyl-de Groot, Carin A.
2014.
Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?.
Value in Health,
Vol. 17,
Issue. 2,
p.
245.